Initiating selexipag within 12 months of PAH diagnosis may reduce hospitalizations, costs

NASHVILLE, Tenn. — Initiation of oral selexipag within 12 months of pulmonary arterial hypertension diagnosis may reduce all-cause hospitalizations and overall medical costs, according to a new analysis.
“One of the key take-home findings is that earlier initiation of PAH combination therapy can deliver improvement in outcomes, particularly reduction in all-cause hospitalizations,” Sumeet Panjabi, PhD, Senior Director, Real World Value & Evidence, Janssen Scientific Affairs, told Healio. “PAH patients exhibit high rates of hospitalizations including ICU admissions

NASHVILLE, Tenn. — Initiation of oral selexipag within 12 months of pulmonary arterial hypertension diagnosis may reduce all-cause hospitalizations and overall medical costs, according to a new analysis.
“One of the key take-home findings is that earlier initiation of PAH combination therapy can deliver improvement in outcomes, particularly reduction in all-cause hospitalizations,” Sumeet Panjabi, PhD, Senior Director, Real World Value & Evidence, Janssen Scientific Affairs, told Healio. “PAH patients exhibit high rates of hospitalizations including ICU admissions